Back <<


Ponatinib Facilitates Treatment-free Remission by P075 Inducing Deep Molecular Responses

Friday, November 11, 2016

Multiple trials now demonstrate the potential for success and the safety of an attempt at treatment-free remission (TFR) in patients with sustained deep molecular response to tyrosine kinase inhibitors (TKIs) [1,2,3]. We describe two patients who remain in treatment-free remission after achieving undetectable BCR-ABL with ponatinib on the phase II PACE trial, despite being multiply resistant/intolerant to other agents or carrying the T315I mutation.

Download the article